Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 12, Number 4, 2007

Efficacy of samarium 153 and strontium 89 treatment for bone metastases in prostate cancer patients: monotherapy vs. treatment combined with external beam radiotherapy. Preliminary report

Maciej Bączyk, Piotr Milecki, Piotr Martenka, Jerzy Sowiński

Summary:

Background: Approximately 60–80% of metastatic prostate cancer patients suffer from pain
caused by bone metastases. Bone metastases have a negative impact on patient
performance status.
Aim: The aim of study was to compare the effi cacy of treatment with strontium 89 or samarium
153 in monotherapy vs. radioisotope treatment combined with external beam radiotherapy (EBRT) in prostate cancer patients with bone metastases.
Materials/Methods: We retrospectively analyzed one hundred (n=100) metastatic prostate cancer patients aged between 53 and 84 years, who we divided into four treatment
groups: 30 pts received Sr-89 monotherapy; 30 patients received Sm-153 monotherapy;
20 pts received Sr-89 combined with EBRT; and 20 pts received Sm-153 combined with EBRT. Follow-up was 4 months. All patients prior to therapy had their bone metastases confi rmed by bone scan examination. Pathologic fractures were excluded and the nature of metastases (osteoblastic/mixed) was evaluated with X-ray fi lms and/or CT and/or MRI. Sr-89 therapy consisted of a standard dose of 150MBq, while Sm-153 was administered proportionally to body weight (37MBq/kg). In combined treatment groups EBRT was given to the dominant metastatic site with 8Gy in one fraction or 20Gy in fi ve daily fractions. Treatment
effi cacy was determined by change in pain intensity evaluated according to visual
analogue scale (VAS), changes in Karnofsky performance status (KPS) and in the use of analgesics.
Results: Complete pain relief (VAS<3) was observed in 33% and 40% of patients in Sr-89
and Sm-153 monotherapy groups and in 50% and 60% of patients treated with Sr-89 and Sm-153 therapy combined with EBRT, respectively. Unsatisfactory response to treatment (VAS>5) was noted in 20% of patients in both monotherapy groups and in 10% and 15% of patients in Sm-153 and Sr-89 combined with EBRT, respectively. Decrease in pain intensity and in the use of analgesics as well as improvement in performance status were statistically signifi cant for combined therapy vs. monotherapy (p<0.05). Treatment was well tolerated, with 3 patients
suffering from severe pancytopenia and 22 patients with mild leucopenia and/or
thrombocytopenia.

Conclusions: Radioisotope therapy with Sr-89 or Sm-153 combined with external beam radiotherapy in comparison with radioisotope monotherapy improves effi cacy of treatment.
Treatment toxicity is low.

Signature: Rep Pract Oncol Radiother, 2007; 12(4) : 211-216

FULL TXT (PDF: 0,08MB)

« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2